Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol in Septic Patients
NCT06209268Not yet recruiting
- Sponsor
- University of Split School of Medicine
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
01
Overview
Randomised, double-blind trial in sepsis comparing Paricalcitol Group with Placebo Group (2 arms). Primary endpoint: Survival at 28 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
paricalcitol
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06209268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209268.